HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by HARPER, M. J. K. Articles by WALPOLE, A. L. Search for Related Content PubMed Articles by HARPER, M. J. K. Articles by WALPOLE, A. L.

Trans-1-(p-β-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene (I.C.I. 46,474), given by mouth, was most effective in terminating early pregnancy in rats on the fourth day after mating. A single intravenous dose was effective on day 4 but even early on day 5 large doses had little effect.

A single oral dose on day 1 or 2 sufficient to prevent implantation completely, caused accelerated tubal transport of the eggs and their premature expulsion from the uterus. This was partially blocked by progesterone and appears to be an oestrogenic effect. The corresponding dose on day 3 or 4 did not affect egg transport or development. After giving the compound on day 4, substantial but diminishing numbers of unimplanted eggs were recovered from the uterus up to day 11 of 'pregnancy'. Such blastocysts could be induced to implant in a proportion of rats by giving a single large injection of oestrogen at the same time as the compound (on day 4) or a progressively smaller dose up to day 11.

These results support the hypothesis (Harper & Walpole, 1966) that I.C.I. 46,474 can prevent implantation in rats by counteracting the 'oestrogensurge' on day 4 necessary for its induction. They further suggest that the compound persists for some days in the uterus.

This article has been cited by other articles:

				V. C. Jordan Tamoxifen or Raloxifene for Breast Cancer Chemoprevention: A Tale of Two Choices Point Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2207 - 2209. [Full Text] [PDF]

				Y. Zeng, M. Yokohira, K. Saoo, H. Takeuchi, Y. Chen, K. Yamakawa, Y. Matsuda, Y. Kakehi, and K. Imaida Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor Carcinogenesis, June 1, 2005; 26(6): 1109 - 1116. [Abstract] [Full Text] [PDF]

				E. V. Jensen and V. C. Jordan The Estrogen Receptor: A Model for Molecular Medicine Clin. Cancer Res., June 1, 2003; 9(6): 1980 - 1989. [Abstract] [Full Text] [PDF]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				J. D. Sherman Tamoxifen and Prevention of Breast Cancer Toxicology and Industrial Health, January 1, 1998; 14(4): 485 - 499. [PDF]